Hong Kong Stocks Movement | JINHAI MED TECH (02225) Surges Over 41% in Afternoon Trading, Cumulative Gain Exceeds 80% Post-Earnings, Previously Raised Capital Through Share Placement for Potential M&A and Investment Projects

Stock News2025-09-10

JINHAI MED TECH (02225) surged over 41% in afternoon trading, with cumulative gains exceeding 80% following its earnings release. As of press time, the stock rose 41.54% to HK$0.92, with trading volume reaching HK$24.8559 million.

On the news front, JINHAI MED TECH recently released its interim results, reporting group revenue of S$14.529 million, down 43.98% year-over-year, while net loss attributable to shareholders widened by 69.67% to S$10.253 million.

The company previously announced a share placement of 120 million new shares, representing approximately 2.27% of the enlarged share capital. The net proceeds of approximately HK$161 million are intended to fund potential acquisitions of healthcare-related projects and/or investments in healthcare-related industries, research and development expenses, and general working capital.

Notably, on July 2nd, Shanghai Jinhai Medical Technology Co., Ltd., a wholly-owned subsidiary of JINHAI MED TECH, entered into a five-year cooperation framework agreement with Ningbo Weierkaidi Medical Device Co., Ltd., a wholly-owned subsidiary of David Medical Device Co., Ltd. (300314.SZ). Under this agreement, Shanghai Jinhai and David Medical Group will collaborate on endoscope products in international markets, aiming to create competitive high-end medical device solutions for the global market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment